You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Remote Brief Intervention and Referral to Treatment Service for Alcohol (R-BIRT)

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NIAAA

    DESCRIPTIONprovided by applicantSignificanceThe USPHSTFSAMHSACDCand NIAAA have affirmed the importance of screening in medical settings for alcohol consumption that exceeds the NIAAA low risk limitsbrief educational and motivational counseling for those who screen positive or have other evidence of an Alcohol Use Disorderandwhen appropriatereferral to treatmentSBIRTHowevertranslation to clinical p ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Polaris Oncology Survivor Transition POST System

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: 100

    DESCRIPTION provided by applicant By January oncology care providers will be expected to craft Survivorship Care Plans SCPs for all individuals ending active treatment for cancer however there is a lack of systematic study of the impact survivorship planning has on patients providers or healthcare systems The Polaris Oncology Survivorship Transition POST program is a web based sy ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Clinical Trial of ABC in Patients with Refractory Multiple Myeloma

    SBC: Apogee Biotechnology Corporation            Topic: NCI

    DESCRIPTION provided by applicant Multiple myeloma MM is the second most common hematological malignancy in the United States and remains an incurable disease since nearly all MM patients will eventually relapse and develop resistance to currently available drugs Sphingolipid metabolism is being increasingly recognized as a key pathway in tumor biology In particular sphingosine kinases S ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical Investigation of the Ceramide NanoLiposome for Advanced Solid Tumors

    SBC: KEYSTONE NANO, INC.            Topic: 102

    DESCRIPTIONprovided by applicantKeystone Nanoin partnership with the University of Maryland Greenebaum Cancer CenterUMD GCCproposes a multi site clinical evaluation of the Ceramide NanoLiposomeCNLas a novel anti cancer therapeuticThe overall objective of this project is to advance the CNL through a Phase I clinical trialThe results of this trial will support subsequent trials for the intended init ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. TissueCypher Testing for Risk Assessment in Barretts Esophagus

    SBC: Cernostics Inc            Topic: 102

    DESCRIPTION provided by applicant Barrettandapos s esophagus is a pre neoplastic disease that predisposes patients to development of esophageal adenocarcinoma EAC Approximately million people in the US have Barrettandapos s esophagus and they are frequently screened by endoscopy with pathological analyses of esophageal biopsies The goal of the screening is to detect premalignant changes e ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)

    SBC: ImCare Biotech LLC            Topic: NCI

    DESCRIPTIONprovided by applicantHepatocellular carcinomaHCCis usually undetected until its later stageswhere theyear survival rate for patients is less thanHoweverthe survival rate can be as high asif the cancer is detected earlyUnfortunatelyearly detection of HCC is not possible with any screening tests that are currently availablesuch as ultrasound or imaging technologiesAlpha FetoproteinAFPwhic ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: R

    DESCRIPTION provided by applicant The smallpox virus variola has been responsible for the deaths of hundreds of millions of people worldwide Although smallpox was eradicated from the globe in following a valiant immunization campaign existing viral stocks may fall into the hands of those seeking to employ variola as a biological weapon This calls for the development of safe antiviral ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses

    SBC: HAWAII BIOTECH, INC.            Topic: R

    DESCRIPTION provided by applicant The tick borne flavivirus TBFV group includes a number of important human pathogens that result in serious encephalitic or hemorrhagic diseases that are either Category B or C priority pathogens The TBFV are considered to be emerging or re emerging pathogens due to increases in the number of human cases the expansion of geographic distribution and emergen ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. CATHEPSIN L INHIBITORS AS PAN CORONAVIRUS THERAPEUTICS

    SBC: PHELIX THERAPEUTICS LLC            Topic: R

    DESCRIPTION provided by applicant Coronaviruses CoV are RNA viruses that cause gastrointestinal respiratory and neurological symptoms in several mammalian species The outbreak of the severe acute respiratory syndrome CoV SARS CoV in humans was fatal in of infected patients infecting people and killing The recent incidents involving the highly pathogenic Middle East ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Non Spherical Particles for HPLC

    SBC: ADVANCED MATERIALS TECHNOLOGY, INC.            Topic: 100

    DESCRIPTION provided by applicant Extending liquid chromatographic column technology to even higher performance levels has given rise to ultra high pressure liquid chromatography UPLC core shell particle technology and instrumental developments such as lower volumes for injector and detector hydraulics In spite of these advances there is still room for improvement in speed selectivity and ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government